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TO THE EDITOR
We read with interest the publication
by Daniotti et al. (2009) that addresses
an important clinical problem—that of
melanomas arising in pediatric patients.
These lesions pose significant diffi-
culties as they are often difficult to
distinguish from Spitz nevi and the
underlying genetic alterations and tar-
gets for therapy are generally not
known. After screening for a number
of germ-line (CDKN2A, CDK4, and
MC1R) and somatic (CDKN2A, KIT,
BRAF and NRAS) alterations that are
common in adult melanoma, the
authors conclude that genetic altera-
tions of KIT occur frequently in this
subset of melanocytic neoplasms. If
confirmed, this finding could have far-
reaching consequences, as melanomas
with mutations in KIT have been shown
to respond favorably to KIT inhibitors
such as imatinib (Hodi et al., 2008;
Lutzky et al., 2008). The small number
and heterogeneity of cases analyzed are
a general limitation of the study. While
the abstract suggests a larger cohort,
only eight ‘‘pediatric’’ patients were
analyzed for KIT alterations. Only two
of these cases (aged 2 and 6 years) are
clearly pre-pubescent, fitting the defini-
tion of childhood melanoma (Brenn and
McKee, 2008), five are cases of adoles-
cent melanoma (age 14–17 years), and
one case at age 11 is in a gray zone.
In addition to these general con-
straints, there are several reasons that
make us believe that the data do not
support the conclusion of an involve-
ment of KIT in this subset of melanocy-
tic tumors.
Mutation analysis of KIT: Of seven
‘‘pediatric’’ patients analyzed, three
have synonymous base pair changes
(DNA sequence alterations that do not
affect the amino-acid sequence) and
one shows an intronic (i.e., similarly a
non-coding) base pair substitution.
Although these mutations are presented
as somatic alterations, this is unlikely to
be the case. The somatic nature of a
given mutation can be determined only
by demonstrating its absence in the
patient’s normal tissue. Specifically, the
L862L variation found in one patient is
a known single-nucleotide polymorph-
ism (rs3733542) that occurs frequently
in the human population. In any case,
none of the listed alterations would be
expected to have a functional impact
on KIT and the claim of ‘‘sequence
alterations of KIT’’ is unsubstantiated.
Copy number increase of KIT deter-
mined by FISH: The legend of Figure 1
and the methods do not allow sufficient
detail to know what exactly was done.
The panels b, g, l, q show a two-color
hybridization, but it is not stated which
probe is for KIT and what other probe is
used. What is obvious from the panels,
however, is that the number of signals is
identical for both colors in all but one
nucleus in the four cases illustrated. The
only nucleus that shows more than two
signals of either color is in panel g. That
nucleus is significantly enlarged, sug-
gesting that it is polyploid (i.e. that it has
more than two genomes of a normal,
diploid cell). In the setting of polyploidy,
FISH probes for any region of the genome
would show more than two signals. As
nevi and melanomas, in particular spit-
zoid neoplasms that are common in
pediatric patients, often have polyploid
cells, the results of ‘‘low polysomy’’ do
not provide sufficient evidence to claim a
copy number increase specifically target-
ing the KIT locus. In general, FISH can
reliably determine the copy number
increases of only a specific genomic
region, if used in conjunction with
suitable reference probes, ideally target-
ing genomic regions with infrequent
copy number changes in the disease of
interest. We have used comparativeAbbreviations: CGH, comparative genomic hybridization; FISH, fluorescent in situ hybridization
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genomic hybridization (CGH) of more
than 200 tumors of the spectrum of
atypical spitzoid tumors in childhood,
including bona fide melanomas, and
have not observed copy number in-
creases at the KIT locus of chromosome
4 in a single case. Although the CGH
platform we used could have missed
focused aberrations, amplifications at the
KIT locus are typically readily obvious by
CGH (Bastian et al., 1998). In fact,
amplification of the KIT locus detected
by this method helped us discover KIT
mutations in acral and mucosal melano-
mas, as well as melanomas on chroni-
cally sun-damaged skin (Curtin et al.,
2006).
Finally, two of the three ‘‘low-
polysomy’’ and three of the four ‘‘KIT
gene alteration’’ cases that were also
analyzed for BRAF mutations in the
study also harbored BRAF V600E muta-
tions. In melanoma, KIT mutations and
copy number increases are highly
inversely correlated with mutations in
other oncogenes, including BRAF or
NRAS, further questioning a role for KIT
in this setting. After critical analysis of
the data presented, we thus see no
evidence to uphold the statement that
‘‘Cutaneous Melanoma in Childhood
and Adolescence Shows Frequent Gain
of KIT’’, as the title of this paper claims.
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TO THE EDITOR
We are pleased at the interest that Drs
Griewank and Bastian (2010) have
shown in our paper ‘‘Cutaneous Mela-
noma in Childhood and Adolescence
Shows Frequent Loss of INK4A and
Gain of KIT’’ (Daniotti et al., 2009). We
thank them for giving us this opportunity
to discuss our results in more detail,
because it was necessary to summarize
a large body of data in our published
work for the sake of brevity.
Melanoma is rare in pediatric
patients, and is often difficult to diag-
nose because of its atypical presentation
and histological uncertainty (Aldrink
et al., 2009; Ducharme and Silverberg,
2009; Jen et al., 2009; Kirkwood et al.,
2009; Mills and Messina, 2009). In our
institute, a total of about 50 melanoma
patients under 18 years of age have been
treated since 1975, compared with
approximately 800 new cases older than
18years treated each year. On the basis
of the incidence rates recorded by the
Italian Network of Cancer Registries, the
expected number of melanoma cases in
Italy is about 8 per year in children (age
0–14) and 15 per year in adolescents
(age 15–17) (Pastore et al., 2009).
Melanoma and the other solid malig-
nancies of childhood that have an
annual incidence of less than 2 per 1
million are included in a national-scale
cooperative project that is aimed at
improving clinical management and
research, through the development of
diagnostic and therapeutic recommen-
dations (Ferrari, 2009). In this context,
although only a few tissues were avail-
able for research studies, we decided to
proceed with the characterization of
somatic and germinal melanoma-asso-
ciated genetic alterations. To our knowl-
edge, this is the first study evaluating
pediatric lesions for abnormalities in
‘‘melanoma genes,’’ namely, BRAF,
NRAS, KIT, and CDKN2A, and the
patients for germline CDKN2A, CDK4
and MC1R genes.
Although the cases of pediatric
lesions analyzed are too few to allow
any statistical evaluation, the results are
indicative of genetic traits that only
partly overlap with those detected in
adult lesions, pointing to melanoma in
childhood as a suitable setting for
unraveling the novel genetic networks
in this tumor histotype.
In particular, the genetic analysis
carried out showed that pediatric
melanoma lesions show (i) the most
frequent adult melanoma gene muta-
tion activating the BRAF oncogene,
thus representing actual candidates
for therapy with specific targeted
agents; (ii) frequent loss of the CDKN2A
gene, corroborating the existence of
molecular pathogenetic mechanisms
in common with adult melanoma; and
(iii) frequent KIT alterations, which
appear to be a peculiarity of childhood
lesions.
In addition, the analysis of known
melanoma susceptibility genes revealed
a peculiar pattern, evidenced by the
comparison with series of familial
melanoma cases studied in parallel. In
fact, the lack of CDKN2A germline
mutations in the absence of a melanoma
family history was observed. Moreover,
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